The visit included a tour of the new Paul J. DiMare Center and a closed-door meeting with UMass Chan faculty members.

UMass Chan and the entire UMass ecosystem are poised for further breakthrough advances in biomedical research, university leaders and congressional delegation members tell ARPA-H director at Medical School visit.  

Victor Ambros, PhD, shared his gratitude to his wife and collaborator, Rosalind “Candy” Lee, as well as to the Medical School and scientific community, at a celebration of the Nobel Prize in Physiology or Medicine he co-received with Gary Ruvkun, PhD, professor at Harvard Medical School, for their discovery of microRNA.  

The UMass Chan Medical School community embraced its newest Nobel Laureate on Monday, Oct. 7, after Victor Ambros, PhD, was named the co-recipient of the 2024 Nobel Prize in Physiology or Medicine for his co-discovery of microRNA. See how the day unfolded in this video.

Students in the Ambros lab at UMass Chan Medical School and 2006 Nobel Prize winner Craig Mello, PhD, celebrated their mentor, Victor Ambros, PhD, as he received the Nobel Prize in Physiology or Medicine with Gary Ruvkun, PhD, for their discovery of microRNA.  

Although Victor Ambros, PhD, was scheduled to move his lab into a new building today, the announcement that he and Gary Ruvkun, PhD, were awarded the Nobel Prize in Physiology or Medicine for their discovery of microRNA, put those plans were put on hold. Read more about how his day unfolded.  

PhD candidate John Girgenrath has received a competitive award from the Eunice Kennedy Shriver National Institute of Child Health and Human Development to conduct fertility research.

Movies piqued PhD candidate Humberto Ochoa’s interest in science. He’s conducting RNA research in the lab of Nobel Laureate Craig C. Mello, PhD, to understand the national decline in fertility.

PhD student Katya Makeyeva investigates how small RNA pathways regulate gene expression of reproductive cells in the lab of Nobel Laureate Craig Mello, PhD.

Atalanta Therapeutics, a biotech founded by UMass Medical School and three faculty research scientists to pioneer treatment options for neurodegenerative diseases, has launched with financing by venture capital fund F-Prime Capital and strategic collaborations with Biogen and Genentech.

The new vaccines by Pfizer/BioNTech and Moderna use messenger RNA to stimulate the immune system to protect against COVID-19. These vaccines are the first of their kind and researchers at UMass Medical School are among the leading RNA biologists in the world.